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Sickle cell disease (scd) is a hereditary disorder that often results in complications incl- uding acute and chronic pain, severe anaemia, 
infection and stroke.1 The disease primarily affects 
the development of red blood cells, resulting in the 
formation of haemoglobin S (Hb S), an abnormal type 
of haemoglobin which causes red blood cells to become 
sickle-shaped and inflexible. These abnormal cells 
clump together in the arteries, blocking blood flow to 
various organs and causing various complications.1,2 
The most common and severe form of SCD is sickle 
cell anaemia (SCA) which results when both parents 
inherit the Hb S variant; in contrast, sickle cell trait 
(SCT), which occurs when Hb S volume is <50%, is 
less severe.2,3 
Overall, SCD is linked with high morbidity and 
mortality particularly among young children under the 
age of five and adolescents.4–9 In addition, it can have 
adverse social and economic consequences.10 As such, 
both the World Health Organization (WHO) and the 
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abstract: Sickle cell disease (SCD) can significantly impair the health-related quality of life (HRQOL) of children 
and adolescents. This review aimed to assess current evidence regarding the HRQOL of children and adolescents 
with SCD in the Middle East and North Africa region. A systematic search of various databases was conducted 
to identify relevant articles, including MEDLINE® (National Library of Medicine, Bethesda, Maryland, USA), 
Scopus® (Elsevier, Amsterdam, the Netherlands), Cumulative Index to Nursing and Allied Health Literature®, 
Masader (Oman Virtual Science Library, Muscat, Oman) and EBSCOhost (EBSCO Information Services, Ipswich, 
Massachusetts, USA). A total of 533 articles were identified; however, only 10 were eligible for inclusion in the final 
analysis. Results from these studies showed that children and adolescents with SCD had compromised HRQOL 
compared to their healthy peers, particularly in terms of physical, psychosocial, familial, financial and academic 
functioning. Therefore, interventions are necessary to improve overall HRQOL outcomes for this population.
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امللخ�ص: ميكن لداء اخلاليا املنجلية اأن ي�سعف ب�سكل كبري جودة احلياة املرتبطة ب�سحة االأطفال واملراهقني. هدفت هذه املراجعة اإىل تقييم 
االأدلة احلالية املتعلقة باالأطفال واملراهقني امل�سابني بداء اخلاليا املنجلية يف منطقة ال�رشق االأو�سط و�سمال اإفريقيا. مت اإجراء بحث منهجي 
لقواعد البيانات املختلفة لتحديد املقاالت ذات ال�سلة، مبا يف ذلك ميدالين )املكتبة الوطنية للطب، بيثي�سدا، مرييالند، الواليات املتحدة 
االأمريكية(، �سكوب�ض )اأيل�سيفري، اأم�سرتدام، هولندا(، الفهر�ض الرتاكمي للتمري�ض واالأدب ال�سحي املتحالف، م�سادر )مكتبة عمان االفرتا�سية 
للعلوم، م�سقط، عمان(، وايبي�سكو )ايبي�سكو خلدمات املعلومات، اإب�سويت�ض، ما�سات�سو�ست�ض، الواليات املتحدة االأمريكية(. مت حتديد ما جمموعه 
533 مقالة؛ ومع ذلك، كان فقط 10 منها موؤهلني لالإدراج يف التحليل النهائي. اأظهرت نتائج هذه الدرا�سات اأن االأطفال واملراهقني امل�سابني 
بداء اخلاليا املنجلية قد تعر�سوا لنق�ض يف جودة احلياة املرتبطة بال�سحة مقارنة باأقرانهم االأ�سحاء، ال �سيما من حيث االأداء البدين 
والنف�سي واالجتماعي والعائلي واملايل واالأكادميي. لذلك، فاإنه من ال�رشوري القيام بالتدخالت املنا�سبة لتح�سني النتائج االإجمالية جلودة 
احلياة املرتبطة بال�سحة لهذه الفئة من ال�سكان.
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United Nations General Assembly have confirmed 
that SCD represents a global public health problem.11 
Worldwide, approximately 25 million people suffer 
from SCD; according to the WHO, more than 300,000 
infants are born with a major haemoglobin disease 
every year, of which SCD accounts for 200,000 cases.4,12 
Varying rates of SCD have been reported in different 
regions due to differences in Hb S gene prevalence (2–
30%). In the USA, approximately 100,000 are affected 
by SCD, with one in every 365 African-American 
and 16,300 Hispanic-American births, while the SCT 
is reported in one in 13 black or African-American 
babies.2 A recent survey reported that approximately 
12,000–15,000 people were affected in the UK, 
equivalent to one in 4,600 people.13 In the Netherlands, 
800 newborns are born with SCD every year.14
In contrast, the global burden of SCD is more 
pronounced in the Middle East and North Africa 
(MENA) region. In Africa, approximately 10–15 
million people live with SCD, with Congo and Nigeria 
most affected.4,7,15–17 The high prevalence of SCD in 
this region is likely due to the increased frequency 
of consanguineous marriages particularly between 
first-degree relatives.11 High rates of consanguineous 
marriages have been reported in Saudi Arabia (42–
67%), Sudan (44–63%), Qatar (54%), the United Arab 
Emirates (40–54%), Jordan (29–64%), Yemen (40–
45%) and Egypt (21–33%).1,18,19 In the Middle East, 
the highest prevalence of SCD and SCT is in eastern 
Saudi Arabia (2.6% and 21%, respectively).20 In 2015, 
the incidence of paediatric SCA was 2,238 in Egypt 
and 25,375 in Iraq.21 Studies from Oman indicate that 
approximately 3,000 people live with SCD, with an 
estimated 118 new cases every year and SCT present 
in one in 370 live births.22–25
Young children and adolescents are more 
vulnerable to lifelong SCD complications such as vaso-
occlusive crises (VOCs), acute splenic sequestration 
crises, acute chest syndrome (ACS), central nervous 
system infarctions, haemolytic and aplastic crises 
and avascular hip necrosis.5,26,27 In children, the most 
common complication of SCD is painful VOCs.28,29 
These occur when the irregularly-shaped red blood 
cells become stuck in the small vessels, causing 
multiple organ infarctions including kidney, spleen, 
bone and brain infarctions.30 Risk factors for VOC 
include exposure to cold, hypoxia, acidosis, inflamm- 
ation, fatigue, physical activity and emotional stress.31 
A study of Omani children revealed that 22% of 240 
children with SCD developed ACS, with 71% of 
cases preceded by painful VOCs.32 In another study 
of Omani children with SCD, VOCs constituted the 
main reason for admission in 83% of 316 hospital 
admissions over a 12-month period.33
Current management of SCD focuses primarily 
on the maintenance of health and treatment of acute 
and chronic complications. Several important modal- 
ities such as hydroxyurea (HU) therapy and blood trans- 
fusions, have been found to boost patient outcomes.34,35 
In particular, HU therapy reduces the frequency of 
VOCs and ACS thereby reducing the need for blood 
transfusions and associated hospitalisation.36 While 
stem cell transplantation is the intervention most likely 
to be curative in nature, this option is often associated 
with several complications.37
Despite recent advances in SCD treatment, the 
health-related quality of life (HRQOL) of children and 
adolescents with SCD remains poor compared to their 
healthy peers particularly with regards to physical, 
mental, social and academic domains.38,39 Although 
many systematic reviews are available regarding 
HRQOL in children and adolescents with SCD, none 
focus specifically on the MENA region. As outlined 
earlier, the prevalence of SCD is much higher in this 
region; hence, understanding the impact of SCD 
on the HRQOL of children and adolescents in this 
region would be invaluable in order to inform future 
interventions such as premarital genetic counselling 
and potential lifestyle modification strategies, and 
to identify and prioritise patient-care decisions. 
Therefore, this systematic review aimed to summarise 
and analyse the existing empirical literature with 
regards to the HRQOL of children and adolescents 
living with SCD in the MENA region, discuss the 
implications of these findings on research and clinical 
practice and suggest strategies for improving HRQOL 
in this region.
Methods
This systematic review was carried out in accordance 
with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines.40 A 
systematic search of various electronic databases was 
performed to identify articles assessing the HRQOL 
of children and adolescents with SCD in the MENA 
region published between January 2010 and March 
2020 including the MEDLINE® (National Library 
of Medicine, Bethesda, Maryland, USA), Scopus® 
(Elsevier, Amsterdam, the Netherlands), Cumulative 
Index to Nursing and Allied Health Literature®, Masader 
(Oman Virtual Science Library, Muscat, Oman) and 
EBSCOhost (EBSCO Information Services, Ipswich, 
Massachusetts, USA) databases. 
The search terms included the following in 
various combinations: “health-related quality of life”, 
“quality of life”, “sickle cell disease”, “sickle cell anaemia”, 
“Middle East”, “North Africa”, “infant,” “children” and 
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“adolescents”. All full-text peer-reviewed articles were 
included in the final analysis if they met the following 
criteria: (1) the articles constituted research studies 
assessing the HRQOL of children and adolescents 
with SCD aged <21 years; (2) the population of interest 
was relevant to the MENA region; (3) the articles were 
published in English between January 2010 and March 
2020; and (4) the population of interest included all 
SCD genotypes. Articles published before 2010 and in 
languages other than English were excluded, as were 
systematic reviews, meta-analyses, editorials, case 
studies, pilot studies and unpublished research, as 
well as studies focusing on the perspectives of adults, 
caregivers, parents or healthcare providers.
Following the initial literature search, the authors 
screened the titles and abstracts of each relevant 
article to eliminate duplicate results. In addition, the 
reference lists of articles retrieved during the database 
search were reviewed to identify additional articles for 
inclusion in the analysis. Subsequently, two authors 
independently evaluated the full text of each article 
to determine its eligibility according to the inclusion 
criteria, with any disagreements settled by consensus. 
In the third step, the authors independently collected 
and consolidated relevant data from the articles as 
per Garrard’s matrix method including the name 
and profession of the authors, year of publication of 
the article, purpose, design and setting of the study, 
period of recruitment, age group, characteristics and 
size of the sample, type of HRQOL instrument, type 
of rater (i.e. self or proxy) and relevant outcomes 
from the study. A total of 533 articles were initially 
identified during the literature search. After removing 
duplicates, 176 unique articles were available for 
further screening. Of these, 146 articles were removed 
because they did not meet the criteria. After screening 
the full text of the remaining 30 articles, 10 articles 
met the inclusion criteria and were included in the 
final analysis [Figure 1]. 
Two reviewers independently assessed the 
methodological quality of each study using an adapted 
version of the Newcastle-Ottawa Quality Assessment 
Scale, except for mixed-method studies which were 
assessed using the Mixed Methods Appraisal Tool.41,42 
Cross-sectional studies were scored out of 8 points, 
based on sample collection (four items), comparability 
(one item) and outcome calculation (two items). 
Case-control studies were scored out of 9, based on 
sample size (four items), comparability (one item) and 
outcome calculation (three items). Cohort studies were 
scored out of 6, based on sample selection (two items), 
comparability (one item) and outcome measurement 
(two items). Each item within the sample selection and 
outcome criteria received a maximum of one point, 
while items in the comparability criteria received a 
maximum of two points. In cases where there was a 
divergence in scoring, the reviewers discussed the 
item in question until a consensus was reached; if 
necessary, a third reviewer was consulted. Studies with 




A total of 10 articles were included in the systematic 
review [Table 1].21,43–51 Of these, nine were 
observational studies, including five cross-sectional, 
two case-control and two cohort studies.21,44–51 The 
 
Figure 1: Diagram showing the search process used to identify articles for inclusion in the systematic review.
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Table 1: Characteristics of studies assessing the health-related quality of life of children and adolescents with sickle cell disease in the 
Middle East and North Africa region (N = 10)21,43–51
Author 













factors that affect 




Oman Children with 
SCA aged 2–16 
years and their 
caretakers




• Children with SCA had 
reduced HRQOL scores. 
• The lowest scores fell on the 
pain impact subscale, with an 
average of 41 ± 21% (range: 
2.5–100%), suggesting that 
HRQOL is adversely affected 
by pain. 
• In contrast, the highest 
score fell on the Worry II 
subscale, with an average of 





To evaluate the 




Uganda Children with 
SCD aged 8–17 









• HRQOL scores were low 
in the physical functioning, 
emotional functioning 
and academic functioning 
domains.
75%
Salih51 (2019) To examine the 
impact of SCA on 
the QOL of school- 







Sudan Children with 




Self • SCD posed multiple social 
and psychological problems 
that need to be addressed. 
• Common problems 
included enuresis, 
depressive symptoms, 
school absenteeism and 




Cevher et al.47 
(2018)
To evaluate QOL, 
clinical effective- 
ness and satisfac- 
tion in children and 
young adults with 
SCD receiving 
HU therapy
Cohort Turkey Children aged 
7–17 years and 
young adults 
aged 18–22 
years with SCD 
who received 







CHQ-PF50 Self and 
proxy
• Both QOL and adherence 
to HU therapy were low, 
likely due to the lack of 
effectiveness of HU therapy, 
along with comorbidity, 




Essawy et al.21 
(2018)
To evaluate the 




Iraq Children with 
SCA aged 6–12 







• SCA significantly affected 
the QOL of the children. 
• Two-thirds of the children 
had poor QOL, less than a 
quarter had neutral QOL and 
few had good QOL. 
• Severe pain was reported by 
78% of the affected children.
75% 
(6/8)
Senol et al.48 
(2016)
To evaluate QOL, 
clinical effective- 
ness and satisfac- 
tion in patients 




Cohort Turkey Children aged 
5–18 years and 
adults with 
BTM or SCA 
who received 






CHQ-PF50 Proxy • Patients with SCA had 
significantly lower HRQOL 
scores for general health, 
physical activity, role/social 
limitations, parental impact-
time and family activities 
and higher scores for health 




Alharbi et al.44 
(2016)









SCD aged 6–12 







• SCD significantly affected 
most HRQOL domains, 
including physical, social, 


































• Disease severity and 
depression were associated 




HRQOL = health-related quality of life; SCA = sickle cell anaemia; PedsQL™ = Pediatric Quality of Life Inventory™; V4 = Version 4.0; SCD = sickle cell disease; FGDs = focus group 
discussions; QOL = quality of life; HU = hydroxyurea; CHQ-PF50 = Child Health Questionnaire - Parent Form 50; BTM = β-thalassemia major; DFX = deferasirox; WHOQ-
OL-BREF = World Health Organisation Quality of Life Brief Version; SF-36 V2 = 36-item Medical Outcomes Study Short-Form Version 2.
*Methodological quality was assessed using an adapted version of the Newcastle-Ottawa Quality Assessment Scale, except for mixed-method studies, which were assessed using 
the Mixed Methods Appraisal Tool.41,42 Cross-sectional, cohort and case-control studies were scored out of 8, 6 and 9, respectively, with scores of <50% considered to indicate poor 
methodological quality.
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final study used a mixed-method design involving both 
quantitative and qualitative measures.43 Most of the 
authors were nurses, medicine or health sciences faculty 
members, psychiatrists, haematologists, pharmacists 
or geneticists. Four studies were conducted in Saudi 
Arabia, two in Turkey and one each in Iraq, Sudan, 
Uganda and Oman.21,43–51
Most of the studies focused primarily on children 
and adolescents aged 2–18 years.21,43–46,48,50,51 However, 
two studies focused both on paediatric and young 
adult populations aged 18–22 years.47,49 In most cases, 
self-reported measures were applied to children over 
the age of 8 years who were literate and capable of 
comprehension, with caregiver proxy reports utilised 
for those between 2–8 years.21,43–47,49–51 The sample size 
for children and adolescents with SCD or SCA ranged 
from 37–180.21,43–51
measures of health-related 
quality of life
Various tools were used to assess the HRQOL of children 
and adolescents with SCD. Two studies used self-
designed structured questionnaires completed during 
interviews.21,51 Three studies utilised the generic core 
scale of the Pediatric Quality of Life Inventory™ 
(PedsQL™); in addition, another study applied the 
PedsQL™ SCD module scale, Version 4.0.43–46 Two 
studies used the Child Health Questionnaire - Parent 
Form 50.47,48 Finally, the WHO Quality of Life Brief 
Version scale and 36-item Medical Outcomes Study 
Short-Form was applied in one study each.49,50 Apart 
from the self-designed questionnaires, all of these 
instruments have been previously validated for use in 
different populations and various languages.43–50 
domains of health-related 
quality of life 
Four distinct HRQOL domains were identified in the 
studies including physical wellbeing, psychological 
wellbeing, family/financial wellbeing and academic 
functioning.21,43–51 In certain cases, specific findings 
from the studies encompassed more than one of these 
domains because of the interconnected nature of 
HRQOL.
physical well-being 
Boulassel et al. reported that children with SCA in 
Oman demonstrated low HRQOL scores; in particular, 
the lowest scores were found on the pain impact scale 
thereby indicating that HRQOL in this cohort was 
Table 1 (cont’d): Characteristics of studies assessing the health-related quality of life of children and adolescents with sickle cell disease 
in the Middle East and North Africa region (N = 10)21,43–51
Author 








Instrument Rater Relevant findings Quality 
of study*
Al Jaouni et 
al.49 (2013)
To assess the 
HRQOL of patients 
with SCD and to 
measure the impact 
of treatment adher- 
ence on complic- 
ations, disease sev- 
























• Extremely ill patients 
had significantly lower 
HRQOL scores (P = 0.002). 
• Pain was the main cause 
of hospitalisation (51.3%). 
• Patients with painful 
episodes (31.3%) and 
on regular narcotics 
had significantly lower 
HRQOL scores (P <0.001). 
• HRQOL scores 
decreased significantly 
as pain levels increased. 
• Patients with delayed 
treatment or those 
who did not adhere 
to treatment reported 
significantly lower HRQL 
scores (P = 0.001).
75% 
(6/8)













with SCD aged 
14–18 years 







SF-36 V2 Self • Adolescents with SCD 
reported poorer HRQOL 
scores compared to 
healthy adolescents, 
particularly in several 
HRQOL domains, 
including physical 




HRQOL = health-related quality of life; SCA = sickle cell anaemia; PedsQL™ = Pediatric Quality of Life Inventory™; V4 = Version 4.0; SCD = sickle cell disease; FGDs = focus group 
discussions; QOL = quality of life; HU = hydroxyurea; CHQ-PF50 = Child Health Questionnaire - Parent Form 50; BTM = β-thalassemia major; DFX = deferasirox; WHO- 
QOL-BREF = World Health Organisation Quality of Life Brief Version; SF-36 V2 = 36-item Medical Outcomes Study Short-Form Version 2.
*Methodological quality was assessed using an adapted version of the Newcastle-Ottawa Quality Assessment Scale, except for mixed-method studies, which were assessed using 
the Mixed Methods Appraisal Tool.41,42 Cross-sectional, cohort and case-control studies were scored out of 8, 6 and 9, respectively, with scores of <50% considered to indicate 
poor methodological quality.
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adversely affected by pain.46 In Uganda, Kambasu et 
al. observed low scores in terms of physical, emotional 
and academic functioning among adolescents with 
SCD.43 According to Cevher et al., both quality of 
life and adherence to HU therapy was low among 
paediatric and young adult patients in Turkey; this was 
attributed to the lack of effectiveness of HU therapy, 
in addition to comorbidity, concomitant drug use and 
side-effects.47 
In Iraq, Essawy et al. concluded that SCA 
significantly affects the quality of life of children, with 
more than two-thirds of the cohort noted to have poor 
quality of life; moreover, the majority (78%) reported 
being in severe pain.21 Among a cohort of SCD patients 
in Saudi Arabia, Al Jaouni et al. observed that those 
who were extremely ill demonstrated significantly 
lower HRQOL scores, with HRQOL scores decreasing 
significantly as pain levels increased.49 In addition, 
patients with delayed or low adherence to treatment 
reported lower HRQL scores.49 Finally, in another study 
set in Saudi Arabia, Amr et al. showed that adolescents 
with SCD had poorer HRQOL scores compared to 
healthy adolescents, particularly in terms of physical 
functioning, body pain and general health.50
psychological well-being
In Sudan, Salih confirmed that SCD caused multiple 
social and psychological problems among school-
aged children, with enuresis, depressive symptoms, 
school absenteeism and deterioration in academic 
performance being most common.51 Additionally, 
Sehlo and Kamfar reported associations between 
poor quality of life and disease severity and depression 
among children with SCD in Saudi Arabia.45
family and financial well-being 
In Turkey, Senol et al. reported significantly lower 
scores among a cohort of children and adolescents with 
SCA for various HRQOL-related subscales including 
general health, physical activity-related limitations, 
physical functioning, parental impact-time and family 
activities compared to patients with β-thalassaemia 
major.48 In addition, the former group demonstrated 
significantly higher scores in terms of health transition 
compared to the latter.48
academic functioning
Alharbi et al. found that SCD significantly affected 
most HRQOL domains in a group of children in 
Saudi Arabia including physical, social, emotional and 
academic well-being domains.44
Discussion
Children with SCD undergo frequent hospitalisation 
due to painful crises which can affect a myriad of other 
facets of life including academic achievement, school 
attendance, social activities and sleep quality.29,52 
Moreover, SCD can affect familial relationships and 
the ability to engage in routine family activities; for 
caregivers, looking after a child with SCD can represent 
an emotional and financial burden.53 Individuals with 
SCD also encounter stigma for a variety of reasons 
such as race, disability status, socioeconomic status, 
chronic pain and delayed growth and puberty.54 
This systematic review examined the existing 
empirical literature regarding the HRQOL of children 
and adolescents with SCD in the MENA region. 
Overall, this population demonstrated poor HRQOL in 
all domains compared to their healthy peers including 
physical, psychological, familial, academic, social and 
financial functioning.21,43–51 Palermo et al. reported 
similar findings in a case-control study comparing 120 
healthy children to 58 children with SCD.55 Using the 
Child Health Questionnaire, the researchers found 
that the physical, psychological and social wellbeing of 
children with SCD was reduced in comparison to the 
healthy control group.55 After applying the PedsQL™ 
instrument, Dale et al. found that 63%, 28% and 55% of 
124 children and adolescents with SCD were at risk of 
physical disability, poor social functioning and reduced 
academic performance, respectively.39 Such findings 
highlight the need for urgent strategies to improve the 
HRQOL of children and adolescents with SCD. 
Pain is a significant predictor for poor HRQOL 
among children and adolescents with SCD and 
a primary indicator of impaired physical and 
psychological functioning.56 Thornburg et al. found 
that children with SCD undergoing HU therapy 
demonstrated better physical and cognitive function 
compared to those who could not take the drug due to 
the extent of the disorder.57 Panepinto et al. revealed 
that poor physical HRQOL scores were correlated 
with clinical comorbidities, older age and lower family 
income.58 Pain has also been positively associated with 
increased maternal and caregiver stress and impaired 
family functioning, thereby leading to poor HRQOL 
outcomes.56 These findings are supported by those of 
other studies.46,59 As such, careful pain assessment at 
home and prompt management is recommended in 
order to promote resilience among children with SCD 
and increase their quality of life.
Menezes et al. observed statistically significant 
gender differences in most HRQOL domains.52 
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However, contradictory findings have been reported 
regarding the effect of gender on pain sensation among 
children and adolescents with SCD. According to 
Andong et al., adolescent girls with SCD demonstrated 
significantly lower levels of physical activity and 
physical pain; in contrast, Kambasu et al. found that 
pain rates were higher in female children with SCD 
compared to their male counterparts.43,60 Therefore, 
further studies are needed to better understand gender 
differences in pain perception among children and 
adolescents with SCD so as to tailor pain management 
strategies accordingly. 
Various studies have reported poor cognitive and 
psychosocial performance in children and adolescents 
with SCD.58,61,62 In a study conducted in India, Patel and 
Pathan reported that children with SCD demonstrated 
low HRQOL scores in in physical, psychosocial and 
cognitive areas.61 These results are supported by 
other studies which revealed that children with SCD 
had lower self-esteem than healthy children.58,62 With 
regards to family, Wonkam et al. found that mothers 
of children with SCD had a higher risk of depression 
compared to mothers with healthy children.59
Families with children affected by SCD often face 
financial challenges. In many developing countries, 
national health insurance or social welfare programmes 
are lacking, thus placing the financial burden of care 
for children with chronic diseases on the individual 
family. In Nigeria, Lagunju et al. observed that families 
of children with SCD often experienced severe 
hardship due to the child’s medical expenses, adversely 
affecting the family’s basic needs such as housing and 
food; moreover, loss of employment resulting from 
time spent caring for a child with SCD also contributed 
significantly to this burden.34 Therefore, countries in 
the MENA region should take steps to help improve 
existing financial support systems for families affected 
by paediatric SCD, perhaps through the provision of 
social welfare subsidies or programmes.
Various studies have shown that children with 
SCD exhibit poor academic functioning compared 
to healthy children, with pain once again found to 
be a significant predictor of such outcomes.44,52,56 
Indeed, children and adolescents with SCD are often 
absent from school, thereby missing out on important 
educational experiences and daily social activities due 
to frequent hospitalisation secondary to pain crises, 
depression, social stigma and poor social support 
systems.44,52 Thus, it is necessary for educators to take 
necessary steps to improve the academic functioning of 
children with SCD, for instance by establishing school- 
or peer-led support groups and special extracurricular 
classes for affected children, or by allowing special 
leeway with regards to high rates of absenteeism for 
medical reasons.
Lack of awareness of the disease has been 
linked with poor HRQOL outcomes among children 
and adolescents with SCD, especially as awareness 
is usually poor among both affected patients and 
caregivers. Shahine et al. found that an increase in 
awareness on the part of the caregiver was significantly 
associated with a decrease in the frequency of 
hospitalisation among children with SCD.38 Another 
study carried out by Al-Azri et al. indicated that the 
quality of life of children with SCD in Oman remained 
low primarily because of a lack of awareness of the 
disease.63 Therefore, health promotion and educational 
programmes are recommended to increase awareness 
of SCD and promote mandatory premarital screening 
to reduce the incidence of the disease in the MENA 
region. 
Social support can have a major impact on the 
resilience of children with SCD such as that offered by 
family members, teachers, peers and friends. Several 
studies have concluded that greater parental support 
and involvement is significantly linked to decreased 
depressive symptoms and better quality of life in 
children with SCD.45,64 Play therapy is a potential option 
to help children with SCD to express their emotions, 
improve communication with caregivers and peers and 
encourage socialisation. Similarly, Pandarakutty et al. 
reported that a nurse-led filial therapy and educational 
intervention resulted in a significant improvement in 
HRQOL scores among a group of children with SCD 
in Oman, particularly in terms of reducing emotions, 
improving knowledge, enhancing parental support 
and reinforcing family relationships.65
implications for future 
research
The findings of this systematic review underline 
an urgent need for practical measures to improve 
the HRQOL of children and adolescents with 
SCD in the MENA region. Such initiatives should 
focus on increasing knowledge and awareness of 
SCD, developing support groups to enhance the 
psychological wellbeing of children and adolescents 
with SCD and their caregivers, mitigating the 
economic burden of care on the families of children 
with SCD and strengthening existing family, social 
and academic support systems. Further studies are 
therefore necessary to help design, implement and 
assess the effectiveness of such strategies in this region.
limitations 
This research was subject to certain limitations. A 
meta-analysis could not be conducted to determine 
correlations between variables due to the differences 
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in statistical analyses across studies. In addition, 
articles focusing on HRQOL outcomes of children and 
adolescents with SCD in the MENA region which were 
published in other languages could not be included 
in the final analysis, possibly resulting in the lack of 
inclusion of relevant non-English language studies.
Conclusion
A systematic review of studies assessing the HRQOL 
of children and adolescents with SCD in the MENA 
region revealed that the HRQOL of this population 
was poor in comparison to healthy children in all 
domains including physical, psychological, familial, 
academic, social and financial functioning. As such, 
healthcare providers, educators and policymakers 
should implement strategies to improve the 
HRQOL of this group. The authors recommend 
the implementation of mandatory awareness and 
premarital screening programmes, thereby increasing 
understanding, reducing stigma and minimising 
the incidence of hereditary diseases such as SCD. 
In addition, interventions such as play therapy may 
help to encourage socialisation, reduce psychological 
stress and strengthen familial bonds. Finally, existing 
financial support systems should be strengthened so 
as to alleviate the economic burden of medical care on 
affected families.  
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